Sacituzumab Tirumotecan Shows Survival Benefit in Advanced Endometrial Cancer

In the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study (NCT06132958), sacituzumab tirumotecan (sac-TMT) demonstrated clinically meaningful survival benefits compared with standard chemotherapy in patients with previously treated advanced or recurrent endometrial cancer, according to findings presented at the ESMO Congress 2026.

During an interview, Domenica Lorusso, MD, PhD, director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X in Milan, Italy, discusses the significance of the findings and the potential impact of sac-TMT as a treatment option for patients with this disease, highlighting the magnitude of benefit observed with the investigational treatment compared with standard of care, particularly in terms of overall survival, progression-free survival, and tumor response.

According to Lorusso, sac-TMT was associated with a 32% reduction in the risk of death and a 41% reduction in the risk of disease progression compared with standard chemotherapy. She emphasized that these results were not only statistically significant but also clinically relevant, highlighting the potential importance of the treatment for patients whose disease has progressed after previous therapy.

Lorusso also notes that approximately twice as many patients experienced tumor shrinkage with sac-TMT compared with chemotherapy. This difference in tumor response, along with the reported survival benefit, supports this agent as an effective option in pretreated endometrial cancer.

When discussing what patients should consider when speaking with their care teams about sac-TMT, she emphasizes the significance of having another treatment option in this setting. The findings provide a basis for discussions about expected treatment benefits, the likelihood of tumor response, and how sac-TMT may compare with available chemotherapy options.

Overall, Lorusso characterizes the TroFuse-005 findings as convincing, citing the magnitude of benefit across key clinical outcomes. The results may offer a meaningful new option for patients with previously treated advanced or recurrent endometrial cancer if this agent becomes available.